What are the key financial outcomes from the third quarter of 2025?

The 8-K filing announces the release of Johnson & Johnson's sales and earnings for the third quarter ended September 28, 2025. Specific figures and performance details are available in the attached press release (Exhibit 99.1) and supplementary sales data (Exhibit 99.2).

What is the significance of the announced Orthopaedics business separation?

Johnson & Johnson has announced its intent to separate its Orthopaedics business. This strategic decision indicates a potential restructuring of the company's portfolio, which could allow for greater focus and specialized investment in both the remaining JNJ businesses and the separated Orthopaedics entity.

When can investors expect more details on the Orthopaedics business separation?

The 8-K filing, issued on October 14, 2025, announces the intent to separate the Orthopaedics business. Further details regarding the timeline, structure, and financial implications of this separation would likely be communicated in subsequent filings and investor communications.

Where can I find the detailed financial information for Q3 2025?

Detailed financial information, including sales data and condensed consolidated statements of earnings for the third quarter and nine months ended September 28, 2025, can be found in the press release dated October 14, 2025 (Exhibit 99.1) and the Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings (Exhibit 99.2) attached to this 8-K filing.

JNJ 8-K: Earnings & Results

Summary

Johnson & Johnson has filed an 8-K report highlighting key developments from its third quarter of 2025. The company announced its sales and earnings results for the quarter ended September 28, 2025, providing investors with updated financial performance data. This report also contains a significant strategic announcement regarding the company's intention to separate its Orthopaedics business. This separation could reshape JNJ's business portfolio and potentially unlock value for shareholders by allowing each segment to focus on its distinct growth opportunities.

Key Highlights

1Johnson & Johnson announced third quarter 2025 sales and earnings results.
2The company has formally declared its intention to separate its Orthopaedics business.
3This strategic move suggests a potential future restructuring of JNJ's core operations.
4The 8-K filing includes press releases detailing the Q3 financial performance and the Orthopaedics business separation.
5Investors will want to review the detailed Q3 financial data for insights into operational performance across JNJ's segments.

JOHNSON & JOHNSON 8-K Report, Financial Results (Oct 14, 2025)

Summary

Key Highlights

Frequently Asked Questions